Sandbox carlos: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 3: Line 3:
::* '''1.Primary pulmonary infection in patients low risk persistence/complication:''' Antifungal treatment not generally recommended. Treat fever weight loss and/or fatigue.
::* '''1.Primary pulmonary infection in patients low risk persistence/complication:''' Antifungal treatment not generally recommended. Treat fever weight loss and/or fatigue.


1.1 Uncomplicated acute coccidioidal pneumonia
1.1'''Uncomplicated acute coccidioidal pneumonia'''
1.1.1 For many (if not most) patients, management may rely on periodic reassessment of symptoms and radiographic findings to assure resolution without antifungal treatment.
:::* 1.1.1 For many (if not most) patients, management may rely on periodic reassessment of symptoms and radiographic findings to assure resolution without antifungal treatment.
1.1.2 Indications for antifungal therapy:
:::* 1.1.2 Indications for antifungal therapy:
:::* Immunosupression (AIDS,therapy with high-dose corticosteroids, receipt of TNF-alpha, receipt of an organ transplant)
:::* Immunosupression (AIDS,therapy with high dose corticosteroids, receiptients of TNF-alpha, receiptients of an organ transplant)
:::* Diabetes
:::* Diabetes
:::* Preexisting cardiomyopathy
:::* Preexisting cardiomyopathy
:::* Pregnancy (third trimester)
:::* Pregnancy (third trimester)
:::* Filipino or african
:::* Filipino or african
:::* weight loss of 110%, intense night sweats persisting longer than 3 weeks, infiltrates involving more than one-half of one lung or portions of both lungs, prominent or persistent hilar adenopathy, anticoccidiodial complement-fixing antibody concentrations in excess of 1:16,
:::* Weight loss of 110%
1.1.3 Antifungal regimenes
:::* Intense night sweats persisting longer than 3 weeks
:::* Preferred: oral azole antifungal agents at dosages of 200–400 mg per day. Courses of typically recommended treatment range from 3 to 6 months.
:::* Infiltrates involving more than one-half of one lung or portions of both lungs
:::* Prominent or persistent hilar adenopathy
:::* Anticoccidiodial complement-fixing antibody concentrations in excess of 1:16
 
:::*'''1.1.3 Antifungal regimenes'''
:::* Preferred: Oral azole antifungal agents at dosages of 200–400 mg qd. Courses of typically recommended treatment range from 3 to 6 months.





Revision as of 15:33, 22 July 2015

  • 1.Primary pulmonary infection in patients low risk persistence/complication: Antifungal treatment not generally recommended. Treat fever weight loss and/or fatigue.

1.1Uncomplicated acute coccidioidal pneumonia

  • 1.1.1 For many (if not most) patients, management may rely on periodic reassessment of symptoms and radiographic findings to assure resolution without antifungal treatment.
  • 1.1.2 Indications for antifungal therapy:
  • Immunosupression (AIDS,therapy with high dose corticosteroids, receiptients of TNF-alpha, receiptients of an organ transplant)
  • Diabetes
  • Preexisting cardiomyopathy
  • Pregnancy (third trimester)
  • Filipino or african
  • Weight loss of 110%
  • Intense night sweats persisting longer than 3 weeks
  • Infiltrates involving more than one-half of one lung or portions of both lungs
  • Prominent or persistent hilar adenopathy
  • Anticoccidiodial complement-fixing antibody concentrations in excess of 1:16
  • 1.1.3 Antifungal regimenes
  • Preferred: Oral azole antifungal agents at dosages of 200–400 mg qd. Courses of typically recommended treatment range from 3 to 6 months.


  • 1.1 Primary pulmonary infection in patients with increased risk of complications or dissemination:
  • Preferred regimen in mild to moderate disease: Itraconazole solution 200 mg PO bid or IV q12h Template:OR Fluconazole 400 mg PO q24h for 3–12 months
  • Locally severe or disseminated disease: Amphotericin B 0.6–1 mg/kg per day by 7 days THEN 0.8 mg/kg every other day or liposomal amphothe B 3-5 mg/kg/d IV or ABLC 5 mg/kg/d IV, until clinical improvement (usually several wks or longer in disseminated disease), followed by itra or flu for at least 1 year.
  • Note (1): Some use combination of Ampho B & Flu for progressive severe disease; controlled series lacking.
  • Note (2): Consultation with specialist recommendation, surgery may be required.
  • Meningitis:
  • Adult:
  • Preferred regimen: Fluconazole 400–1,000 mg po q24h indefinitely
  • Alternative regimen: Amphotericin B IV as for pulmonary (above) + 0.1–0.3 mg daily intrathecal (intraventricular) via reservoir device Template:OR itra 400–800 mg q24h Template:OR Voriconazole
  • Note (1): Some use combination of Amphotericin B and Flu for progressive severe disease; controlled series lacking.
  • Child:


  • 2.Special considerations for HIV/AIDS patients
  • 2.1 Focal Pneumonia
  • 2.1.1 Mild Infections: Fluconazole 400 mg PO daily OR Itraconazole 200 mg PO BID
  • Alternative regimen for patients who failed to respond to fluconazole or itraconazole
Posaconazole 200 mg PO BID (BII), or

Voriconazole 200 mg PO BID (BIII)

  • 2.1.2 Severe Non-Meningeal Infection: Amphotericin B deoxycholate 0.7–1.0 mg/kg IV daily, Lipid formulation amphotericin B 4–6 mg/kg IV daily, Duration of therapy: continue until clinical improvement, then switch to an azole


  • 3. Meningingeal infections
  • Preferrered regimen: Fluconazole 400–800 mg IV or PO daily
  • Alternative regimen:

• Itraconazole 200 mg PO TID for 3 days, then 200 mg PO BID (BII), or

• Posaconazole 200 mg PO BID (BIII), or

• Voriconazole 200–400 mg PO BID (BIII), or

• Intrathecal amphotericin B deoxycholate, when triazole antifungals are ineffective (AIII):::* Chonic suppressive therapy: Fluconazole 400 mg PO daily (AII), or Itraconazole 200 mg PO BID


  • Note (1): Monitor 5-FC levels and CBC to avoid bone marrow suppression.
  • Alternative regimen: Above without flucytosine, but need to treat for 4-6 wks of ampho B or 12 wks of fluconazole 1200 mg/day (especially if neutropenic).
  • Fluconazole alternative: itraconazole (not as effective). Ampho B alternative liposomal AmB 4-6 mg/kg/day IV.
  • Maintenance phase: fluconazole 200 mg PO once daily life long or discontinue maintenance fluconazole when CD4 >200 × 6 mos and completed 10 wks rx minimum and asymptomatic. CSF pressure OP > 250 mm H2O: remove CSF fluid until pressure drops 50%, then daily LP with same rule until OP <200 mm H2O.




References